Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine

Raw, Rachael K.; Rees, Jon; Kelly, Clive; Wroe, Caroline; Chadwick, David

doi:10.1016/j.vaccine.2021.11.090

Cited by 18 publications

(26 citation statements)

References 18 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our prospective cohort study on a large number of health-care professionals vaccinated with two doses of the BNT162b2 vaccine for SARS-Cov-2 demonstrates that self-reported adverse events are most frequently mild and correlate with sex, age, BMI, and previous COVID-19, and are more prevalent after the second dose, in partial agreement with previous reports [ 10 , 11 ]. Furthermore, the presence of adverse events, particularly fever, lymphadenopathy, and myalgia, predicts the magnitude of serum IgG response 10 days following the second dose.…”

Section: Discussionsupporting

confidence: 91%

Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals

et al. 2022

View full text Add to dashboard Cite

Short-term adverse events are common following the BNT162b2 vaccine for SARS-Cov-2 and have been possibly associated with IgG response. We aimed to determine the incidence of adverse reactions to the vaccine and the impact on IgG response. Our study included 4156 health-care professionals who received two doses of the BNT162b2 vaccine 21 days apart and obtained 6113 online questionnaires inquiring about adverse events. The serum response was tested in 2765 subjects 10 days after the second dose. Adverse events, most frequently a local reaction at the site of injection, were reported by 39% of subjects. Multivariate analysis showed that female sex (odds ratio—OR—1.95; 95% confidence interval—CI—1.74–2.19; p < 0.001), younger age (OR 0.98 per year, p < 0.001), second dose of vaccine (OR 1.36, p < 0.001), and previous COVID-19 infection (OR 1.41, p < 0.001) were independently associated with adverse events. IgG response was significantly higher in subjects with adverse events (1110 AU/mL—IQR 345-1630 vs. 386 AU/mL, IQR 261-1350, p < 0.0001), and the association was more pronounced in subjects experiencing myalgia, fever, and lymphadenopathy. We demonstrate that a more pronounced IgG response is associated with specific adverse events, and these are commonly reported by health care professionals after the BNT162b2 vaccine for SARS-Cov-2.

show abstract

Section: Discussionsupporting

confidence: 91%

Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The second group consisted of women with histories of PCR-or antibody-confirmed COVID-19 infection. Knowing a survey respondent's history of COVID-19 infection may be important in the evaluation of vaccine tolerability during pregnancy because studies published to date have shown poorer vaccine tolerability in individuals with a history of COVID-19 infection, which mainly manifests in response to the first dose of the BNT162b2 mRNA COVID-19 vaccine [22][23][24].…”

Section: Discussionmentioning

confidence: 99%

“…No such difference in firstdose tolerability was shown in the COVID-19-free pregnant group compared with controls. As the first dose is less well tolerated after COVID-19 infection in the general population it is likely that the mechanisms of immunotolerance are probably more responsible in reducing the number of adverse events among COVID-19-exposed pregnant women than in the COVID-19-free group [22][23][24]28]. There is a lack of information in the current literature regarding the effect of COVID-19 infection on the immune system in pregnant women.…”

Section: Discussionmentioning

confidence: 99%

Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals

et al. 2022

View full text Add to dashboard Cite

The tolerance and safety of vaccination in pregnancy should be assessed in local populations based on ethnic differences across countries. Therefore, this study aimed to determine the tolerability of the BNT162b2 mRNA vaccination in pregnancy in a Polish population. An online questionnaire enquiring about the safety and tolerability of the BNT162b2 mRNA vaccine was distributed to pregnant and non-pregnant female healthcare professionals who had voluntarily received one or two doses of the COVID-19 vaccine in Poland. The two groups were compared simultaneously considering the COVID-19 infection status before vaccination. Compared with that noted in the control group, pregnant women in the COVID-19-free group were less likely to have fever (p = 0.002) or gastrointestinal symptoms (p = 0.009) after the second dose. In the COVID-19-exposed group, pregnant women were less likely to experience local skin reactions (p = 0.009), and myalgia (p = 0.003) after the first dose. After the second dose, the only noticeable difference was a lower incidence of myalgia (p = 0.001) in pregnant women. The tolerability of the BNT162b2 mRNA COVID-19 vaccine was similar in both the groups. No severe local, generalised, or pregnancy complications related to mother or foetus were observed. Good tolerability of the BNT162b2 mRNA COVID-19 vaccine in pregnancy in the Polish population may facilitate the decision to vaccinate pregnant women against COVID-19.

show abstract

“…Porównywanie korzyści dla tych osób z korzyściami dla osób niebędących ozdrowieńcami nie jest proste. Niepożądane odczyny poszczepienne występują u tych osób częściej po zastosowaniu BNT162b2/ Pfizer i, co ciekawe, tylko przy pierwszej dawce [71]. Sugeruje się więc, że dawka dla ozdrowieńców mogłaby być obniżona.…”

Section: Niepożądane Odczyny Poszczepienne W Trakcie Badań Klinicznyc...unclassified

“…Dlatego zdecydowano się nie rekomendować szczepień, początkowo przez 6 miesięcy, a potem 3 miesiące od infekcji SARS--CoV-2. Zwrócono na to uwagę również w innych publikacjach [71,72]. Na pewno warto badać wpływ szczepień u ozdrowieńców z long COVID-19.…”

Section: Niepożądane Odczyny Poszczepienne W Trakcie Badań Klinicznyc...unclassified

Adverse effects of vaccinations and potential therapies against COVID-19

Wasiak¹,

Rieske²

2022

pja

View full text Add to dashboard Cite

StrESzczEnIEW artykule przedstawiono, że terapie przeciwwirusowe są zdecydowanie bardziej szkodliwe oraz mniej skuteczne i dostępne niż szczepienia. Terapie przeciwwirusowe nie są skuteczne w zasadzie w II i III fazie choroby. Stosowanie terapii przeciwwirusowych u wszystkich pacjentów spowodowałoby wystąpienie u nich licznych działań niepożądanych, a tylko 10% chorych przechodzi z I do II fazy i wymaga takiego leczenia. Szansa na wyleczenie pacjentów z COVID-19 w II i III fazie choroby gwałtownie się zmniejsza. Szczepienia są natomiast bardzo skuteczne. Niepożądane odczyny poszczepienne występują rzadko; trwają intensywne badania zmierzające do wyjaśnienia ich etiopatogenezy. Z biotechnologicznego punktu widzenia szczepienia prowadzą do wytworzenia immunoterapii zbliżonej do CAR-T czy przeciwciał monoklonalnych, które działają od pierwszego dnia infekcji, a nie pierwszego dnia wystąpienia objawów, kiedy pacjenci mogą rozpocząć jakąś terapię. W przypadku COVID-19 stwierdzono zdecydowaną przewagę szczepienia nad terapią farmakologiczną. Ponieważ nie u wszystkich pacjentów szczepienie może być skuteczne, badania nad terapią powinny być intensywnie prowadzone. Prawidłowa farmakoterapia zależy od szybkiej współpracy diagnostów z lekarzami, a także od opracowania testów umożliwiających dobrać terapię i stwierdzenie, u kogo choroba, taka jak COVID-19, przejdzie z I fazy w II fazę. Zaszczepieni pacjenci zareagują najprawdopodobniej lepiej na stosowane terapie. Słowa kluczowE SARS-CoV-2, COVID-19, szczepionka, niepożądany odczyn poszczepienny (NOP), wzmocnienie zależne od przeciwciał (ADE).

show abstract

Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine

Cited by 18 publications

References 18 publications

Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals

Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals

Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals

Adverse effects of vaccinations and potential therapies against COVID-19

Contact Info

Product

Resources

About